Search

Displaying results 4491 - 4500 of 10000 in total
  1. Drug

    Talaporfin

    go.drugbank.com/drugs/DB11812
    Investigational

    Talaporfin has been investigated for the treatment of Port-Wine Stain and Benign Prostatic Hyperplasia.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings
  2. Drug

    Tilarginine

    go.drugbank.com/drugs/DB11815
    ApprovedInvestigationalWithdrawn

    Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.

    Synonyms: N(G)-Monomethyl-L-arginine, N(G)-Methylarginine
  3. Drug

    Mocetinostat

    go.drugbank.com/drugs/DB11830
    Investigational

    Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Sapanisertib

    go.drugbank.com/drugs/DB11836
    Investigational

    Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  5. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  6. Drug

    Varespladib

    go.drugbank.com/drugs/DB11909
    Investigational

    Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.

    Categories: Heterocyclic Compounds, 2-Ring, Phospholipases A, antagonists & inhibitors
  7. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: REMLEAS™ hard capsules 40mg
  8. Drug

    Safingol

    go.drugbank.com/drugs/DB11924
    Investigational

    Safingol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.

    Categories: Protein Kinase C, antagonists & inhibitors
  9. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Henagliflozin

    go.drugbank.com/drugs/DB11939
    Investigational

    Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.